News

Hospital News11d
Study shows promise for treating progressive multiple sclerosis
New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...
Multiple Sclerosis News Today12d
Cognitive symptoms, mood disorders vary with MS subtype
Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...
GEN - Genetic Engineering and Biotechnology News3d
Multiple Sclerosis Society Announces MS Research and Funding Opportunities
Researchers still don’t fully understand the cause of multiple sclerosis or why the rate of progression is so difficult to ...
Hosted on MSN1mon
Tolebrutinib Benefits Non-Relapsing Secondary Progressive Multiple Sclerosis
SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years
Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with ...
2 Minute Medicine4d
Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis
In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...
2 Minute Medicine6d
Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates
In concurrent randomized controlled trials (GEMINI 1 and GEMINI 2) of patients with relapsing multiple sclerosis (RMS), ...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...